339538-65-7

Basic information

• Product Name: 2-(4-TRIFLUOROMETHYLPHENYL)NICOTINIC ACID
• Synonyms: 2-(4-TRIFLUOROMETHYLPHENYL)-3-PYRIDINECARBOXYLIC ACID;2-(4-TRIFLUOROMETHYLPHENYL)NICOTINIC ACID
• CAS NO: 339538-65-7
• Molecular Formula: C₁₃H₈F₃NO₂
• Molecular Weight: 267.2
• Product Categories: Carboxylic Acids;Pyridines;Carboxylic Acids
• Mol File: 339538-65-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 346.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.377±0.06 g/cm3(Predicted)
• PKA: 1.73±0.36(Predicted)
• CAS DataBase Reference: 2-(4-TRIFLUOROMETHYLPHENYL)NICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TRIFLUOROMETHYLPHENYL)NICOTINIC ACID(339538-65-7)
• EPA Substance Registry System: 2-(4-TRIFLUOROMETHYLPHENYL)NICOTINIC ACID(339538-65-7)

Safety Data

• Hazardous Substances Data: 339538-65-7(Hazardous Substances Data)

Upstream product

• 339538-64-6 ethyl 2-(4-(trifluoromethyl)phenyl)nicotinate 
• 35905-85-2 2-bromonicotinic acid 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 2942-59-8 2-chloronicotinic acid 
• 1452-94-4 ethyl 2-chloronicotinate 
• 256397-61-2 6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxylic acid 

Downstream Products

• 339538-66-8 7-{[2-(4-Trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Triamide-substituted heterobicyclic compounds

The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.